Symbiotec Pharmalab IPO
Historical offer record. This offer is closed for applications. Prices and subscriptions describe the past offer; GMP observations are unofficial past records, not current quotes or listing predictions.
Data provider: FinAPI. This is a third-party summary, not an official prospectus. Read our data limitations and editorial policy.
Price band
₹938 – ₹988
Lot size
15 shares
Offer application amount
₹14,820
Issue size
₹1757 Cr
Historical offer amount for 1 lot at the upper issue price. Confirm the lot size and application terms in the issuer prospectus.
Reported IPO schedule
| Open date | 24 Aug 2026 |
| Close date | 27 Aug 2026 |
| Allotment finalisation | 28 Aug 2026 |
| Refund initiation | 31 Aug 2026 |
| Shares credited to demat | 31 Aug 2026 |
Issue size
Historical GMP observations
GMP is an unofficial, unregulated indicator and not a reliable predictor of listing price. Observations supplied by FinAPI; an underlying GMP source link was not provided.
Historical reported subscription multiples
These are source observations, not live subscription updates. Multiples are supplied by FinAPI. Share counts are omitted because their units are not confirmed. Check the exchange's offer record for the final subscription figures.
About Symbiotec Pharmalab
Symbiotec Pharmalab is a pharmaceutical and biotechnology company with over 30 years of experience. It mainly manufactures Corticosteroid and Steroidal Hormone APIs, which are important ingredients used to make medicines.
Company summary supplied by FinAPI. Read the prospectus for the issuer's disclosures and audited financials.
Use of proceeds
| Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the Company | ₹112.50 |
| General corporate purposes | ₹- |
Offer documents and primary references
Read the issuer's offer document and any corrigenda for the full disclosures. A third-party details page is a summary; SEBI filing access does not imply an endorsement of the offer or this website.
IPO information is sourced from public feeds and shown for general information only. It is not a recommendation to apply for this or any IPO. IPOs are equity investments and carry market risk; listing gains are not guaranteed and SME IPOs are especially volatile. Grey Market Premium (GMP) is unofficial and not endorsed by SEBI or the exchanges. Equity IPOs are applied for through a demat and trading account, not through mutual fund distribution services. Read the RHP and consult a SEBI-registered investment adviser before investing.